Indeed, hypertension may be the most physiologic target for natriuretic peptide therapy based upon the evidence of a relative deficiency of ANP and BNP in human hypertension and blood pressure reduction being the signature pharmacologic action of MANP. The gene discussed is NPPA; the disease is Hypertension.